China's Strategy Asks How to Increase Optionality Without Abandoning Speed

The Pattern We're Seeing

Most of the biotech teams we work with have Chinese dependencies, but what catches them off guard is this:

• Partnership term sheets requiring supply chain diversification within 6 months

• Acquirers flagging China-only clinical data as a diligence issue

• A board asking 'if BIOSECURE expands, what's our switching timeline?' (and realizing the answer is '12+ months')

If this hasn't been on your radar, perhaps it's time to ask, 'If we lost access to our primary Chinese CDMO tomorrow, how long to switch to an alternate?'

If the answer's '6+ months' or 'we'd have to re-qualify from scratch,' you have exposure and should consider contingency.

What Prepared Companies Are Doing

The teams moving proactively are building structured optionality without abandoning Chinese relationships. This means they can pivot if policy or partnership requirements change.

Three areas getting focused attention:

1. Map exposure by critical path instead of vendor list

Most companies have a spreadsheet of Chinese vendors. The prepared ones have mapped which dependencies actually gate their IND or BLA filing.

What this means:

• Tox studies: Can you refile with ex-China data if a partner requires it?

• Drug substance/drug product: Is your tech transfer package documented well enough to move to an alternate site?

• Analytics and assays: Are your biomarker assays validated at labs outside China?

The distinction: Critical path (can't file without it) vs. convenient (replaceable if needed).

What boards are asking: 'If policy changes or a partner flags this, what's our switching timeline and cost?'

Having this mapped before they ask changes the conversation from 'we'll look into it' to 'here's our exposure and contingency plan.'

2. Qualify alternates now, even if you don't switch

The companies with real optionality aren't waiting to be forced. They're qualifying alternate ex-China vendors proactively—even while continuing with their primary Chinese partner.

The 'warm standby' approach:

• Identify 1-2 alternate vendors (US, EU, South Korea, India)

• Run 1-2 small validation lots to prove your tech transfer package works

• Document the process so switching isn't starting from zero

Why this matters:

Waiting until you're forced to switch means 6-12 months to qualify a new vendor. If you've already done the groundwork, that timeline drops to 6-12 weeks.

The benchmark: Most companies are targeting under 30% single-jurisdiction critical-path exposure. Not moving everything out of China—ensuring no single jurisdiction can stop your program.

The tradeoff: Costs money upfront (validation lots, vendor qualification). The ROI is insurance—and increasingly, what partners expect in diligence.

3. Design trials for data portability from the start

China's enrollment velocity is a major advantage. But a China-only dataset is increasingly a liability for US/EU partnerships.

What's working:

Harmonized endpoints: Align biomarkers and endpoints so data is acceptable to FDA, EMA, and NMPA without separate bridging studies.

Parallel site activation: Open a few ex-China sites alongside China enrollment. You keep China's speed while building a diversified safety/efficacy profile.

Why this matters for exits: Multiple acquirers have recently flagged China-only datasets in diligence—not because the data is bad, but because it limits regulatory and commercial optionality.

The constraint: Adds cost and complexity to trial design. But if your endgame is US/EU partnership or acquisition, it's often unavoidable.

One Company's Approach

A Phase 2 oncology biotech realized their China exposure had grown organically—primary CDMO, backup CDMO, three CROs, and 70% of Phase 2 enrollment all in China.

Their board asked: 'If BIOSECURE expands or a partner requires diversification, what's our timeline?'

What they did:

• Mapped critical path: DS/DP manufacturing and tox studies were true blockers

• Qualified alternates: Ran validation lots with a South Korean CDMO and US tox lab over 4 months

• Opened ex-China sites: Added US and EU sites to Phase 2, keeping China as primary enrollment

• Documented data residency: Confirmed where patient data was hosted, updated contracts

Timeline: ~6 months from board question to documented contingency plans.

Result: Their next financing round, the lead investor specifically called out their 'proactive China risk management.' They didn't eliminate China exposure—they demonstrated they'd thought through optionality.

How to Actually Approach This

Step 1: Map your true exposure (2-4 weeks)

Start with critical path questions:

• What do we need to file our IND/BLA?

• Which dependencies are single-source from China?

• If we lost access tomorrow, what's our switching timeline?

Not a risk register—understanding which risks actually gate your program.

Step 2: Prioritize based on critical path and switching cost (1-2 weeks)

Focus on:

• High priority: Critical path + long switching time (DS/DP manufacturing, tox studies)

• Medium priority: Important but replaceable (certain CRO services, analytics)

• Low priority: Convenient but not blocking (consumables, routine testing)

Step 3: Build contingency for high-priority items (3-6 months)

For critical-path dependencies:

• Identify 1-2 alternate vendors

• Run small validation lots (test the tech transfer, don't just get quotes)

• Document the process so switching is defined, not theoretical

If you lack technical bandwidth: This is often where companies bring in interim CMC expertise—not to run the transfer, but to ensure your tech transfer package is solid.

Step 4: Design new work with portability in mind (ongoing)

For new trials or manufacturing builds:

• Consider geographic diversity from the start

• Build data residency requirements into contracts

• Document IP provenance as you go (easier than reconstructing later)

What to brief your board:

Not 'here's our risk' (they know). Instead: 'Here's our exposure map, the critical-path items, our contingency timeline for each, and what we're building.'

This shifts from anxiety to oversight.

When This Is Premature

This makes sense for:

• Phase 2+ companies (partnerships/exits are near-term)

• Companies with critical manufacturing in single jurisdictions

• Anyone with board/investor pressure on China risk

Probably too early if:

• You're pre-IND with minimal China dependencies

• You're discovery-stage (no manufacturing or clinical exposure)

• Your China relationships are for non-critical-path work

Honest answer: Early-stage companies often lean on China for speed and cost, and that's fine. But heading toward IND or partnerships, having a contingency plan matters—not because you'll execute it, but because partners will ask.

What Are You Seeing?

Are you facing board or investor questions about China exposure? And what's the actual constraint—technical (switching is hard), financial (alternates cost more), or strategic (you want to keep China relationships but need documented optionality)?

Worth comparing notes.

—Roop